Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366911 | 0.91 | L3MBTL1 (0.36) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL17495786 | 0.86 | POLB (0.33) | CASRCA1CA2CA9POLB | |
| SCHEMBL10177325 | 0.80 | CCNT1 (0.36) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL10177339 | 0.76 | L3MBTL1 (0.34) | L3MBTL1ELANEPOLBGAAGFER | |
| SCHEMBL17341891 | 0.76 | L3MBTL1 (0.37) | L3MBTL1ELANE | |
| SCHEMBL12929982 | 0.75 | POLB (0.42) | CA1CA2CA9POLBGAA | |
| SCHEMBL10177324 | 0.75 | CCNT1 (0.40) | CA12CA1CA2CA9POLB | |
| SCHEMBL365347 | 0.74 | L3MBTL1 (0.36) | L3MBTL1CA12CA1CA2CA9 | |
| SCHEMBL366676 | 0.73 | PKM (0.36) | L3MBTL1POLBCCNT1CDK9ACHE | |
| SCHEMBL10177355 | 0.72 | POLB (0.41) | CA1CA2CA9POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2016-09-15 | — | — | US | disclosed |
| US-9381508-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9266913-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-12-17 | — | — | US | disclosed |
| US-9200021-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8975443-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8841487-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBOTT LABORATORIES (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371446-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | L3MBTL1 2695/4885CASR 2972/4885CA12 1261/4885 |
| US-20130217876-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | L3MBTL1 2677/4885CASR 3197/4885CA12 1396/4885 |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | L3MBTL1 2677/4885CASR 3197/4885CA12 1396/4885 |
| US-20150152126-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | L3MBTL1 2677/4885CASR 3197/4885CA12 1396/4885 |
| US-20150360215-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | L3MBTL1 2677/4885CASR 3197/4885CA12 1396/4885 |
| US-20120022252-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PPIP5K2, ITPA | L3MBTL1 2695/4885CASR 2972/4885CA12 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.